AnuoluwapoOluwakemiOsinusiMD

PubMed

• 27 citations
  Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti–Hepatitis C Virus Therapy in Patients With Advanced Liver Disease
  Sarah Kattakuzhy, Eleanor Wilson, Sreetha Sidharthan, Zayani Sims, Mary Ann McLaughlin, Angie Price, Rachel Silk, Chloe Gross, Elizabeth Akoth, Maryellen McManus, Benj...> ;Clinical Infectious Diseases. 2015 Oct 26
• 120 citations
  Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study
  Anita Kohli, A. Osinusi, Zayani Sims, Amy Nelson, Eric G. Meissner, Lisa L Barrett, Dimitra Bon, Miriam M. Marti, Rachel Silk, Colleen Kotb, Chloe Gross, Tim A. Jolley...> ;Lancet. 2015 Mar 21
• 10 citations
  Favorable adverse event profile of sofosbuvir/ribavirin compared to boceprevir/interferon/ribavirin for treatment of hepatitis C
  Shivakumar Narayanan, Kerry Townsend, Thomas Macharia, Adrian Majid, Amy Nelson, Robert R. Redfield, Shyam Kottilil, Rohit Talwani, Anu Osinusi> ;Hepatology International. 2014 Sep 21
• IFNL4-ΔG Genotype is Associated with Slower Viral Clearance in Hepatitis C, Genotype-1 Patients Treated with Sofosbuvir and Ribavirin.
  Meissner, E. G.,Bon, D.,Prokunina-Olsson, L.,Tang, W.,Masur, H.,O'Brien, T. R.,Herrmann, E.,Kottilil, S.,Osinusi, A.> ;J. Infect. Dis.. 2013 Dec 25
• 244 citations
  Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.
  A. Osinusi, Eric G. Meissner, Yu-Jin Lee, Dimitra Bon, Laura Heytens, Amy Nelson, Michael C. Sneller, Anita Kohli, Lisa Barrett, Michael A. Proschan, Eva Herrmann, Bha...> ;JAMA. 2013 Aug 28
• 1 citations
  Boceprevir for HCV in patients with HIV: where next?
  A. Osinusi, Susanna Naggie> ;The Lancet. Infectious Diseases. 2013 Jul 1
• Effect of HIV on liver fibrosis among HCV-infected African Americans.
  Silver, D.,Karnik, G.,Osinusi, A.,Silk, R.,Stabinski, L.,Doonquah, L.,Henn, S.,Teferi, G.,Masur, H.,Kottilil, S.,Fishbein, D.> ;Clin. Infect. Dis.. 2013 May
• 16 citations
  Two independent epidemics of HIV in Maryland.
  Jean K. Carr, Anu Osinusi, Colin Flynn, Bruce L. Gilliam, Varun Maheshwari, Richard Y. Zhao> ;Journal of Acquired Immune Deficiency Syndromes. 2010 Jul 1
• Twice-weekly pegylated interferon-α-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy.
  Murphy, A. A., Herrmann, E., Osinusi, A. O., Wu, L., Sachau, W., Lempicki, R. A., Yang, J., Chung, T. L., Chung, T. L., Wood, B. J., Haagmans, B. L., Kottilil, S., Pol...> ;AIDS. 2011 Jun 1
• HIV/Hepatitis C virus-coinfected virologic responders to pegylated interferon and ribavirin therapy more frequently incur interferon-related adverse events than nonres...
  Osinusi, A., Rasimas, J. J., Bishop, R., Proschan, M., McLaughlin, M., Murphy, A., Cortez, K. J., Polis, M. A., Masur, H., Rosenstein, D., Kottilil, S.> ;J Acquir Immune Defic Syndr. 2010 Mar
• Rapid development of advanced liver fibrosis after acquisition of hepatitis C infection during primary HIV infection.
  Osinusi, A., Kleiner, D., Wood, B., Polis, M., Masur, H., Kottilil, S.> ;AIDS Patient Care STDS. 2009 Jun 01
• Join now to see all